PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Medical - Devices

Healthcare
$25.18 +0.89%

+$0.19 today

Market cap
$1.45B
Beta
0.85
P/E (TTM)
-11.6
EPS (TTM)
-$1.81
52W Low $19.35High $62.17

Volume 2.05M

Average 1.46M

PRCT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

PROCEPT BioRobotics CorporationNASDAQ: PRCT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$13.32M, compared with $3.93M a year earlier. Trailing-twelve-month accounts receivables was -$18.14M. Over 3 fiscal years it compounded at -56.4% a year.

Context

  • Accounts receivables amounted to 0.3% of revenue in FY2025, down 15.7 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$13.32M or moves back toward the trailing-twelve-month quarterly average of -$4.54M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.32M-697.2% QoQ
Last fiscal yearDec 2025
-$898K-97.5% YoY
LTMMar 2026
-$18.14M-25.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-438.9%——
1 year-97.5%——
3-year CAGR-56.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(898K) USD
Year-over-year change
+97.5%

Accounts Receivables vs competitors

How PRCT compares with its peers on the latest reported figures

  • PRCT's LTM Mar 2026 accounts receivables of $18.14M is the largest of the 5 companies compared; the peer median is $1.62M.
  • Its year-over-year change of -25.4% is the lowest of 3, against a peer median of +978.3%.
  • Accounts receivables amounts to 5.6% of revenue for PRCT, versus a peer median of 18.9%.
PRCT Competitors Peer median
Accounts Receivables for PRCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$18.14M -25.4%-56.4%5.6%
SSIISS Innovations International, Inc.LTM Mar 2026$14.56M +1796.8%+131.9%30.0%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$3.13M +159.8%+8.3%7.7%
MBOTMicrobot Medical Inc.LTM Mar 2026$105K ——100.0%
FOCLEDAP TMS S.A. American Depositary SharesLTM Jun 2024$0 —-35.0%0.0%
Peer median (excluding PRCT) $1.62M+978.3%+8.3%18.9%

Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(59.85M)(87.15M)(105.9M)(91.41M)(95.57M)
Depreciation & Amortization3.32M2.84M3.81M5.23M6.39M
Deferred Income Tax451K0000
Stock-Based Compensation3.8M10.34M19.13M31.84M47.6M
Change in Working Capital(4.71M)(11.49M)(26.16M)(47.33M)(7.84M)
Accounts Receivables(2.91M)(10.81M)(33.1M)(35.96M)(898K)
Inventory(6.12M)(15.25M)(9.75M)(17.24M)(14.5M)
Accounts Payables812K3.96M5.79M(2.15M)6.65M
Other Working Capital3.52M10.61M10.9M8.02M909K
Other Non-Cash Items(345K)5.08M1.12M2.45M433K
Operating Cash Flow(57.33M)(80.38M)(108M)(99.21M)(48.99M)
Capital Expenditures(592K)(2.65M)(25.21M)(4.41M)(9.36M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(592K)(2.65M)(25.21M)(4.41M)(9.36M)
Debt Repayment01.2M000
Common Stock Issued172.36M0161.71M164.52M11.19M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.04M2.42M6.09M15.6M0
Financing Cash Flow262.12M3.61M167.8M180.13M11.19M
Effect of Forex Changes0000(74K)
Net Change in Cash204.19M(79.42M)34.59M76.5M(47.22M)
Free Cash Flow(57.93M)(83.04M)(133.21M)(103.62M)(58.34M)

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Intrinsic Alpha fair value

Locked

Current Price

$25.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.